To further evaluate the anti-HCC effects the PCSK9 inhibitor PF-06446846, we treated NSG mice bearing HepG2 tumors with PF-06446846 and inoculated these mice with 5×106 AFP-specific TCR-T cells (Figure 7A). Here, PCSK9 is linked to hepatocellular carcinoma.